General aspects of anti-angiogenesis and cancer therapy

Theresa G. Zogakis, Steven K. Libutti

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Angiogenesis is the outgrowth of new vessels from pre-existing ones. Tumour growth and metastasis is dependent on angiogenesis and many stimulatory and inhibitory factors have been described which play an active role in this process. Inhibition of tumour neovasculature may be one strategy to inhibit tumour growth. Naturally occurring inhibitors of angiogenesis have been discovered and synthetic agents have been designed. Many of these inhibitors are currently being evaluated in clinical trials for the treatment of cancer. This review discusses the mechanism of action of these anti-angiogenics as well as a description of the clinical trials in which they are being evaluated. 2001 Ashley Publications Ltd Papers of special note have been highlighted as: • of interest •• of considerable interest.

Original languageEnglish (US)
Pages (from-to)253-275
Number of pages23
JournalExpert Opinion on Biological Therapy
Volume1
Issue number2
StatePublished - 2001
Externally publishedYes

Fingerprint

Tumors
Neoplasms
Angiogenesis Inhibitors
Clinical Trials
Therapeutics
Growth
Publications
Neoplasm Metastasis

Keywords

  • Angiogenesis
  • Cancer therapy
  • Carboxyamido-triazole
  • Endostatin
  • IL-12
  • Matrix metalloproteinases
  • Sitramin
  • Thalidomide
  • VEGF

ASJC Scopus subject areas

  • Pharmacology
  • Biochemistry, Genetics and Molecular Biology(all)
  • Genetics
  • Immunology

Cite this

General aspects of anti-angiogenesis and cancer therapy. / Zogakis, Theresa G.; Libutti, Steven K.

In: Expert Opinion on Biological Therapy, Vol. 1, No. 2, 2001, p. 253-275.

Research output: Contribution to journalArticle

Zogakis, TG & Libutti, SK 2001, 'General aspects of anti-angiogenesis and cancer therapy', Expert Opinion on Biological Therapy, vol. 1, no. 2, pp. 253-275.
Zogakis, Theresa G. ; Libutti, Steven K. / General aspects of anti-angiogenesis and cancer therapy. In: Expert Opinion on Biological Therapy. 2001 ; Vol. 1, No. 2. pp. 253-275.
@article{7e189f9335464b028afd4aa0aa8c6380,
title = "General aspects of anti-angiogenesis and cancer therapy",
abstract = "Angiogenesis is the outgrowth of new vessels from pre-existing ones. Tumour growth and metastasis is dependent on angiogenesis and many stimulatory and inhibitory factors have been described which play an active role in this process. Inhibition of tumour neovasculature may be one strategy to inhibit tumour growth. Naturally occurring inhibitors of angiogenesis have been discovered and synthetic agents have been designed. Many of these inhibitors are currently being evaluated in clinical trials for the treatment of cancer. This review discusses the mechanism of action of these anti-angiogenics as well as a description of the clinical trials in which they are being evaluated. 2001 Ashley Publications Ltd Papers of special note have been highlighted as: • of interest •• of considerable interest.",
keywords = "Angiogenesis, Cancer therapy, Carboxyamido-triazole, Endostatin, IL-12, Matrix metalloproteinases, Sitramin, Thalidomide, VEGF",
author = "Zogakis, {Theresa G.} and Libutti, {Steven K.}",
year = "2001",
language = "English (US)",
volume = "1",
pages = "253--275",
journal = "Expert Opinion on Biological Therapy",
issn = "1471-2598",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - General aspects of anti-angiogenesis and cancer therapy

AU - Zogakis, Theresa G.

AU - Libutti, Steven K.

PY - 2001

Y1 - 2001

N2 - Angiogenesis is the outgrowth of new vessels from pre-existing ones. Tumour growth and metastasis is dependent on angiogenesis and many stimulatory and inhibitory factors have been described which play an active role in this process. Inhibition of tumour neovasculature may be one strategy to inhibit tumour growth. Naturally occurring inhibitors of angiogenesis have been discovered and synthetic agents have been designed. Many of these inhibitors are currently being evaluated in clinical trials for the treatment of cancer. This review discusses the mechanism of action of these anti-angiogenics as well as a description of the clinical trials in which they are being evaluated. 2001 Ashley Publications Ltd Papers of special note have been highlighted as: • of interest •• of considerable interest.

AB - Angiogenesis is the outgrowth of new vessels from pre-existing ones. Tumour growth and metastasis is dependent on angiogenesis and many stimulatory and inhibitory factors have been described which play an active role in this process. Inhibition of tumour neovasculature may be one strategy to inhibit tumour growth. Naturally occurring inhibitors of angiogenesis have been discovered and synthetic agents have been designed. Many of these inhibitors are currently being evaluated in clinical trials for the treatment of cancer. This review discusses the mechanism of action of these anti-angiogenics as well as a description of the clinical trials in which they are being evaluated. 2001 Ashley Publications Ltd Papers of special note have been highlighted as: • of interest •• of considerable interest.

KW - Angiogenesis

KW - Cancer therapy

KW - Carboxyamido-triazole

KW - Endostatin

KW - IL-12

KW - Matrix metalloproteinases

KW - Sitramin

KW - Thalidomide

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=0035294634&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035294634&partnerID=8YFLogxK

M3 - Article

C2 - 11727534

AN - SCOPUS:0035294634

VL - 1

SP - 253

EP - 275

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

SN - 1471-2598

IS - 2

ER -